View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
 PRESS RELEASE

Macerich Reports Fourth Quarter 2025 Earnings Results

Macerich Reports Fourth Quarter 2025 Earnings Results SANTA MONICA, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- The Macerich Company (NYSE: MAC) has released its Fourth Quarter 2025 Earnings Results and Supplemental Information by posting it to the Investor Relations section of its website at . As previously announced, management will hold a conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) today, Wednesday, February 18, 2026, to discuss quarterly results. Participants who wish to join the conference by telephone must register using the dial-in registration link below to...

 PRESS RELEASE

Genelux Corporation to Participate in Upcoming Conferences

Genelux Corporation to Participate in Upcoming Conferences WESTLAKE VILLAGE, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that the Company will participate in two upcoming conferences. Oppenheimer Healthcare Life Sciences Conference: Thomas Zindrick, President, CEO and Chairman of the Board; Matt Pulisic, Chief Financial Officer; and Dr. Jason Litten, Chief Medical Officer, will participate in a virtual fireside chat on Wednesday, February 25, 2026, at 11:20 a.m. ET.TD Cowen 46th Annual Health Care Conference: Th...

 PRESS RELEASE

Macerich Declares the Quarterly Dividend on Its Common Shares

Macerich Declares the Quarterly Dividend on Its Common Shares SANTA MONICA, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- The Board of Directors of The Macerich Company (NYSE: MAC) declared a quarterly cash dividend of $0.17 per share of common stock. The dividend is payable on March 30, 2026, to stockholders of record at the close of business on March 16, 2026. About Macerich Macerich (NYSE: MAC) is a fully integrated, self-managed, self-administered real estate investment trust (REIT). As a leading owner, operator, and developer of high-quality retail real estate in densely populated and ...

 PRESS RELEASE

Macerich Schedules Fourth Quarter 2025 Earnings Release and Conference...

Macerich Schedules Fourth Quarter 2025 Earnings Release and Conference Call SANTA MONICA, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) -- WHAT: Macerich (NYSE: MAC) Schedules Fourth Quarter 2025 Earnings Release and Conference Call WHEN: Earnings Results will be released after market on Wednesday, February 18, 2026. Management will hold a conference call at 2:00 pm Pacific Time (5:00 pm Eastern Time) on that same day to discuss quarterly results. WHERE: Participants who wish to join the conference by telephone must register using the dial-in registration link below to receive the dial-in nu...

 PRESS RELEASE

Macerich Announces Tax Treatment of 2025 Dividends

Macerich Announces Tax Treatment of 2025 Dividends SANTA MONICA, Calif., Jan. 15, 2026 (GLOBE NEWSWIRE) -- The Macerich Company (NYSE: MAC) today announced the tax treatment for dividend distributions taxable in 2025 on its Common Stock. During the calendar year ended December 31, 2025, Macerich paid dividends of $0.68 per share. The 2025 dividends are classified for income tax purposes as follows for The Macerich Company, Common Stock, CUSIP #554382101: Record DatePayable DateRate per Share2025 Taxable Ordinary Dividends2025 Section 199A Dividends*2025 Qualified Dividends*2025 Total Cap...

Alpine Select AG: 2 directors

Two Directors at Alpine Select AG bought 5,280 shares at 9.000CHF. The significance rating of the trade was 54/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearl...

 PRESS RELEASE

Genelux Corporation Announces Upcoming Virtual Fireside Chat Hosted by...

Genelux Corporation Announces Upcoming Virtual Fireside Chat Hosted by Titan Partners WESTLAKE VILLAGE, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick, President, CEO and Chairman of the Board; Matt Pulisic, Chief Financial Officer; and Dr. Jason Litten, Chief Medical Officer, will participate in a virtual fireside chat hosted by Boris Peaker, PhD, Managing Director and Senior Equity Research Analyst at Titan Partners, on Monday, January 19, 2026 at 9:00 a.m. PT. A live webcast of the fireside ...

 PRESS RELEASE

Genelux Corporation Announces Pricing of $20.0 Million Underwritten Pu...

Genelux Corporation Announces Pricing of $20.0 Million Underwritten Public Offering of Common Stock WESTLAKE VILLAGE, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Genelux Corporation (“Genelux”) (Nasdaq: GNLX), a late clinical-stage immuno-oncology company, today announced the pricing of an underwritten public offering of 6,666,667 shares of its common stock at a price to the public of $3.00 per share. All of the shares in the offering are to be sold by Genelux. The gross proceeds to Genelux from the offering are expected to be approximately $20.0 million, before deducting underwriting disc...

 PRESS RELEASE

Genelux Corporation Announces Proposed Public Offering of Common Stock

Genelux Corporation Announces Proposed Public Offering of Common Stock WESTLAKE VILLAGE, Calif., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Genelux Corporation (“Genelux”) (Nasdaq: GNLX), a late clinical-stage immuno-oncology company, today announced that it has commenced a proposed underwritten public offering of its common stock. In addition, Genelux expects to grant the underwriter a 30-day option to purchase up to an additional 15% of the number of shares of common stock sold in connection with the proposed offering. All shares are being offered by Genelux. The proposed offering is subject to ...

 PRESS RELEASE

Genelux Corporation Reports Encouraging Interim Data of Systemic Admin...

Genelux Corporation Reports Encouraging Interim Data of Systemic Administration of Olvi-Vec in Ongoing Lung Cancer Trials -- Interim data from 14 patients with progressive lung cancers in dose-escalation cohorts of systemically administered Olvi-Vec-primed immunochemotherapy across ongoing SCLC and NSCLC trials; enrollment ongoing – -- In platinum-relapsed or platinum-refractory advanced SCLC, two of three partial responses (PRs) occurred in the highest dose cohort tested as of the data review cutoff date (tumor shrinkage of ~55% and ~85%), with three PRs out of nine subjects (33%) across ...

 PRESS RELEASE

Genelux Corporation Announces Appointment of Jason Litten, M.D., as Ch...

Genelux Corporation Announces Appointment of Jason Litten, M.D., as Chief Medical Officer WESTLAKE VILLAGE, Calif., Jan. 02, 2026 (GLOBE NEWSWIRE) --   NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced the appointment of Jason Litten, M.D., as Chief Medical Officer, effective January 2, 2026. Dr. Litten will oversee all clinical development and medical strategy as the company advances Olvi-Vec through multiple upcoming pivotal milestones. “We are excited to welcome Jason, who is widely recognized for his strategic approach to clinical development and commitm...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights.com Daily Ratings Report: December 19, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights.com Daily Ratings Report: December 13, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

 PRESS RELEASE

Genelux Corporation to Participate in a Fireside Chat at Piper Sandler...

Genelux Corporation to Participate in a Fireside Chat at Piper Sandler 37th Annual Healthcare Conference WESTLAKE VILLAGE, Calif., Nov. 26, 2025 (GLOBE NEWSWIRE) -- NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick, President, CEO and Chairman of the Board and Matt Pulisic, Chief Financial Officer, will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on Wednesday, December 3, 2025 at 12:00 p.m. ET in New York, NY. A live webcast of the fireside chat can be found . Following the live webcast, an archiv...

Jan Frederik Slijkerman ... (+5)
  • Jan Frederik Slijkerman
  • Jeroen van den Broek
  • Jesse Norcross
  • Nadège Tillier
  • Timothy Rahill

Coffee, Croissants & Credit/EnBW, Enel, Verizon, Merlin Properties, Co...

Utilities: EnBW 9M25 financial performance slightly down. Enel 9M25 financials in line with expectations. Telecom: Verizon reportedly preparing job cuts. Real Estate: Merlin Properties 9M25: Good results with a strong Madrid office market. Colonial 9M25: Solid results, prime CBD office exposure continues to perform well

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch